TheraVectys SA is considering an initial public offering in Hong Kong, Bloomberg News reported Tuesday, citing people familiar with the matter.

The France- and US-based immunotherapy company is working with advisers on a potential share sale that could raise a few hundred million dollars and may take place as soon as this year, the report said.

Deliberations are ongoing, and no final decision has been made, it added.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)